Tag: targets

Researchers identify possible immune targets in the SARS-CoV-2 genome

Otago researchers studying the COVID-19 virus (SARS-2) have discovered potential target points on its genome, which may contribute to future treatments for the virus. While their laboratory was locked down during the Level 4 period, Ph.D. student Ali Hosseini and Professor Alex McLellan from the Department of Microbiology and Immunology worked from their homes to

New vaccine targets killer disease tuberculosis

There is only one existing vaccine for TB and it is not effective in adults. Researchers at the Centenary Institute and University of Sydney will next test their new vaccine in clinical trials with humans. Australian medical researchers from the Centenary Institute and the University of Sydney have successfully developed and tested on mice a

Alzheimer’s drug trial targets by-product of gum disease

The pharmaceutical company, Cortexyme, Inc. has outlined a trial of potential Alzheimer’s drug that targets toxic substances released by P. gingivalis, a bacteria linked to gum disease. In a poster presented at the Alzheimer’s Association International Conference today (Wednesday, July 17), researchers provided an overview of the development of the drug, known as COR388, and

New insights into treatment targets for men with advanced prostate cancers

A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumors. Using comprehensive genomic profiling (CGP) to analyze thousands of tumor samples from men with advanced prostate cancers, the researchers identified that 57

Deadly meningitis B targets college students

(HealthDay)—College students face a much higher risk for the deadly bacterial infection meningitis B, a new analysis shows. Investigators from the U.S. Centers for Disease Control and Prevention found that students who were aged 18 to 24 were 3.5 times more likely to contract meningitis B than their peers who were not in school. The

New compound targets drug-resistant HIV mutants

Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications. The new compounds work by inhibiting the

FDA targets clinics offering unapproved stem cell therapies

(HealthDay)—The U.S. Food and Drug Administration has launched legal action to stop two stem cell clinics from providing unapproved treatments that have caused serious, long-term harm to some patients. On Wednesday, the FDA filed complaints in federal court seeking permanent injunctions against U.S. Stem Cell Clinic LLC of Sunrise, Fla., and California Stem Cell Treatment

Experimental drug targets prostate cancer’s chief weakness

The National Cancer Institute (NCI) estimate that 164,690 people will be diagnosed with prostate cancer in 2018. They suggest that more than 11 percent of men will receive this diagnosis at some point during their lifetime. Treatments for prostate cancer can include radiation therapy, hormone therapy, and chemotherapy. But unfortunately, in many cases, tumors that

New breast cancer targets

Genome-wide association studies (GWAS) have identified more than 150 genetic variations associated with increased risk for breast cancer. Most of these variants are not located in protein-coding gene regions but are assumed to regulate the expression of certain genes. One way to figure out what these variants are doing is to conduct a cis-eQTL analysis.

Cancer protein could point to new targets for treatment

A new view of a protein frequently mutated in pituitary tumors is overturning conventional wisdom and could point to novel targets for cancer drugs. The protein, a “G protein” called Gαs, initiates messages inside cells. But a single mutation alters Gαs action in a surprising way. The protein’s molecular “off switch” actually switches activity on,

Immune-engineered device targets chemo-resistant lymphoma

Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body’s lymph nodes, which are connected to a network of lymph vessels through which lymphatic fluid flows. The most common type of lymphoma is diffuse large B-cell lymphoma (DLBCL), accounting for about